MDT

96.91

-0.67%↓

147.87

-0.47%↓

VEEV

232.45

-3%↓

HQY

84.34

-10.55%↓

PHR.US

17.13

-0.23%↓

MDT

96.91

-0.67%↓

147.87

-0.47%↓

VEEV

232.45

-3%↓

HQY

84.34

-10.55%↓

PHR.US

17.13

-0.23%↓

MDT

96.91

-0.67%↓

147.87

-0.47%↓

VEEV

232.45

-3%↓

HQY

84.34

-10.55%↓

PHR.US

17.13

-0.23%↓

MDT

96.91

-0.67%↓

147.87

-0.47%↓

VEEV

232.45

-3%↓

HQY

84.34

-10.55%↓

PHR.US

17.13

-0.23%↓

MDT

96.91

-0.67%↓

147.87

-0.47%↓

VEEV

232.45

-3%↓

HQY

84.34

-10.55%↓

PHR.US

17.13

-0.23%↓

Home・Aktien・Lisata Therapeutics

L
Lisata Therapeutics

Geschlossen

2.03 5.18

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

1.95

Max

2.07

Schlüsselkennzahlen
By Trading Economics
Angestellte	26

Dividenden
By Dow Jones
Nächstes Ergebnis	26. Feb. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-5.9M 14M
Vorheriger Eröffnungskurs	-3.15
Vorheriger Schlusskurs	2.03

Lisata Therapeutics Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

12. Jan. 2026, 23:54 UTC

Market Talk

CBA Could Underperform Again in 2026 -- Market Talk

12. Jan. 2026, 23:48 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

12. Jan. 2026, 23:48 UTC

Market Talk

Nikkei May Rise on Weaker Yen -- Market Talk

12. Jan. 2026, 23:43 UTC

Market Talk

Gold Edges Lower on Likely Technical Correction -- Market Talk

12. Jan. 2026, 23:18 UTC

Akquisitionen, Fusionen, Übernahmen

Paramount Sues Warner Bros., Plans Proxy Fight. The Ellisons Aren't Giving Up. -- Barrons.com

12. Jan. 2026, 21:56 UTC

Market Talk

Light & Wonder Gets Positive Outcome From Lawsuit -- Market Talk

12. Jan. 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

12. Jan. 2026, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

12. Jan. 2026, 21:50 UTC

Market Talk

Ergebnisse

Auto & Transport Roundup: Market Talk

12. Jan. 2026, 21:18 UTC

Market Talk

Global Equities Roundup: Market Talk

12. Jan. 2026, 21:18 UTC

Market Talk

Pfizer CEO Sees Large Cash Market for Obesity Drugs -- Market Talk

12. Jan. 2026, 20:54 UTC

Ergebnisse

Gap, Fortinet, and More Stocks That Usually Outperform After Earnings -- Barrons.com

12. Jan. 2026, 20:48 UTC

Market Talk

Oil Futures Settle Higher in Choppy Trade -- Market Talk

12. Jan. 2026, 20:33 UTC

Market Talk

U.S. Natural Gas Jumps on Colder Weather Outlook -- Market Talk

12. Jan. 2026, 20:18 UTC

Akquisitionen, Fusionen, Übernahmen

Credit Agricole Sees Banco BPM Stake Helping 2025 Net by EUR200M >ACA.FR

12. Jan. 2026, 20:18 UTC

Akquisitionen, Fusionen, Übernahmen

Credit Agricole: European Central Bank Approves Crossing of 20% Threshold in Share Capital of Banco BPM

12. Jan. 2026, 19:39 UTC

Market Talk

J&J CEO: Trump Pact Allows Company to Focus on Core Operations -- Market Talk

12. Jan. 2026, 19:36 UTC

Market Talk

Gold and Silver Set New Records on Fed Probe -- Market Talk

12. Jan. 2026, 19:36 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

12. Jan. 2026, 19:33 UTC

Market Talk

Venezuela's 'Proven' Oil Reserves Raises Questions -- Market Talk

12. Jan. 2026, 19:24 UTC

Akquisitionen, Fusionen, Übernahmen

Dynavax: 'Party A' CEO Sent a Non-Binding $15/Shr Proposal on Dec. 23

12. Jan. 2026, 19:22 UTC

Akquisitionen, Fusionen, Übernahmen

Dynavax Files Tender Offer Recommendation Statement Related to Sanofi Deal, Mentions Talks With 'Party A'

12. Jan. 2026, 18:21 UTC

Akquisitionen, Fusionen, Übernahmen

Paramount Plans Proxy Fight to Push Hostile Warner Bid -- 2nd Update

12. Jan. 2026, 18:20 UTC

Akquisitionen, Fusionen, Übernahmen

This French Biotech Stock Surged 1,700% in 2025. Eli Lilly Is Taking an Interest. -- Barrons.com

12. Jan. 2026, 18:19 UTC

Market Talk

Modest Canadian Economic Impact Seen from Venezuela Changes -- Market Talk

12. Jan. 2026, 18:16 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Comcast Could Unlock Value With a Spinoff of NBCUniversal Assets, Analysts Say -- Market Talk

12. Jan. 2026, 18:09 UTC

Market Talk

Global Equities Roundup: Market Talk

12. Jan. 2026, 18:09 UTC

Market Talk

Baidu's Outlook Bodes Well For Shares -- Market Talk

12. Jan. 2026, 18:01 UTC

Akquisitionen, Fusionen, Übernahmen

QXO Is Raising Another $1.8 Billion for Its M&A War Chest -- Barrons.com

12. Jan. 2026, 18:00 UTC

Market Talk

Canada's 'Breakeven' Employment Recalibrating -- Market Talk

Peer-Vergleich

Kursveränderung

Lisata Therapeutics Prognose

Rating-Konsens

By TipRanks

0 ratings

Buy

Halten

Sell

Basierend auf 0 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Lisata Therapeutics – Dist abgegeben haben.

Finanzen

Über Lisata Therapeutics

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.